According to the announcement of the Chinese vaccine manufacturer – National Biotechnology Company (CNBG), a subsidiary of Sinopharm, it has approved the clinical trial of a globulin-based Covid-19 treatment drug. Human immunoglobulin (pH4) was developed from the plasma of a recovered patient on August 30.
This is a new drug that uses biological products to treat, and is also the world’s first Covid-19 specific drug, which is prepared from the plasma of healthy people after being immunized with an inactivated anti-Covid vaccine. -19.
Chu Kinh Tan, the head of the global phase III clinical project of the CNBG Covid-19 vaccine, said: “This drug uses the plasma of recovered patients and immunocompromised patients as the raw material for cell growth. and at the same time gave a very good effect on early and severe patients in the previous emergency use period.”
The drug was announced at the 2021 China International Trade in Services Fair (CIFTIS) being held in Beijing.
In addition to the new drug, CNBG also introduced 6 other anti-epidemic products at the fair, including 2 updated vaccines that are effective against Beta and Delta variants. vaccine recombinant protein and an mRNA vaccine, and another Covid-19 drug based on a monoclonal antibody.
Previously, CNBG has produced plasma products made from donated plasma from recovered patients since early 2020 and this is believed to be an effective treatment for critically ill patients with Covid- 19.
However, CNBG did not disclose where and when it will launch clinical trials. Meanwhile, according to experts, it is not known how long the clinical trials will last because at present there are not too many patients in China.
Experts also note that the drug will be used sparingly for critically ill patients, because it can be expensive, but still cheaper than monoclonal antibody drugs.
According to CNBG, it takes at least a week from plasma collection to preparation of products that can be used on Covid-19 patients. On average, a recovered patient can donate 400ml of plasma to save 2 or 3 patients in critical condition.
Meanwhile, the Thai government’s Center for Covid-19 Situation Administration (CCSA) has asked hospitals across the country to speed up the vaccination of 500,000 pregnant women who are at risk of infection. Covid-19 is high.
According to CCSA Assistant Center Spokesperson, Dr. Apisamai Srirangsan, the Thai government plans to vaccinate 500,000 women over 12 weeks pregnant. So far, only about 45,400 people have received the first dose and about 5,000 have been fully vaccinated.
Concerns about the risk of Covid-19 among pregnant women in Thailand are growing, after the number of new cases increased sharply in the past month. The number of new cases recorded in pregnant women increased from 819 in July to 1,506 on August 28. To date, 69 pregnant women and 29 infants have died from Covid-19.
The Thai government’s Center for Covid-19 Situation Administration has asked hospitals across the country to contact women who are more than 12 weeks pregnant or who have just given birth to receive a Covid-19 vaccine. In addition, Thailand also confirmed the goal of vaccinating at least 70% of people in the at-risk group in 29 provinces and cities in the “dark red” region, which needs to be controlled strictly by the end of the month. this 9.